| Website | phaserx.com |
| Category | BioTech |
| Phone | 206-812-1530 |
| Employees |
| TOTAL | $19M |
| VENTURE FUNDING TOTAL | $19M |
| Series A, 2/08 ARCH Venture Partners 5AM Ventures Versant Ventures | $19M |
PhaseRx is a startup company based in Seattle focused on the delivery of siRNA and other macromolecular therapeutics. The Company has attracted top-tier venture investors and was founded by its President, Robert Overell, Patrick Stayton and Allan Hoffman of the University of Washington, Oliver Press of Fred Hutchinson Cancer Research Center, and Paul Johnson, the Company’s Chief Scientific Officer. PhaseRx was conceived on the basis of using novel polymer technology to deliver siRNA. The Company believes the technology also has significant applications for the delivery of other macromolecular therapeutics.
